Two Stocks Ready To Run Could Go Even Higher On Short Squeeze

New York, NY -- April 3, 2019 -- InvestorsHub NewsWire -- www.nextbigticker.com -- Alternet Systems, Inc. (USOTC: ALYI) and Kali-Extracts, Inc. (USOTC: KALY) both came out with strong business plan supporting news yesterday and both had a jump in average trading volume. Today, both are pushing past Moving Average prices and seeing MACD crosses in spite of large market maker offers that runaway when charged. Yesterday, the short sales reported by FINRA exceeded 60% of total volume on both ALYI and KALY.

ALYI yesterday announced a potential $20 million order for the company’s electric motorcycles that could result from a series of strategic meetings next week. The stock is reacting bullishly and now the short squeeze could add to PPS appreciation.

ALYI is trading way above its $0.014 200 DAY MA and on the verge of breaking through its $0.029 50 DAY MA. The MACD is on its way to a cross and the Candlestick Pattern is Bullish Harami.
ALYI has a 52-Week High of over $0.06 and an analyst recommended Target PPS of $0.09. Momentum today that sees a close above $0.029 can take this stock to the next level all the way back to its $0.06 52-Week High with a potential upside to the $0.09 Target PPS.

KALY revealed yesterday for the first time ongoing patented cannabis extract Type 2 Diabetes Treatment research the company had previously kept under wraps adding to the recently published research results from the company’s pilot Chronic Obstructive Pulmonary Disease (COPD) treatment evaluation. The press release yesterday indicated two more cannabis extract health issue treatments are also soon to be revealed. KALY trading has shot to the OTC top 25 most actively traded list with the PPS edging toward a breakout. The PPS is above the 200 Day MA and has now broken past the 50 Day MA following a MACD cross. The candlestick analysis is indicating VERY BULLISH and now the short squeeze could add to PPS appreciation.

KALY Potential PPS Run From $0.01 to $0.04 On Way To $0.10

KALY has the potential to run from its $0.01 PPS level to $0.10 in the near term. Shortly after the 2018 Q4 acquisition of the patented cannabis extraction process, the company PPS shot from sub-penny land to almost $0.04 on volume that put it in the top 20 most actively traded stocks on the OTC Market. The PPS retraced back to $0.01 and has been holding that price with a healthy trading volume. With KALY’s patented cannabis pharmaceutical research now coming to light, the PPS is positioned to shoot past the recent $0.04 highs to a level putting it on par with some of the other penny cannabis stock contenders. A $0.10 PPS is a reasonable milestone following the company filing its upcoming annual reported expected to include the company posting its first revenue derived from its cannabis extraction process. The company filed an extension on the 2018 annual report with the report itself now expected within the next 15 days.

KALY is providing CBD extracts for over $1 million worth of CBD infused water produced by Puration, Inc. (USOTC: PURA), and KALY has also introduced its own CBD infused gum. KALY is also implementing an extraction lab to process biomass from Nouveau’s (USOTC: NOUV) 100 acer hemp farm.

Following the acquisition of the patented cannabis extraction process late last year and the corresponding jump in price and trading volume, the OTC Markets flagged the company in response to the jump in activity. The company has responded by updating all its OTC Markets required reports. Management is likely to mitigate the OTC Market’s concerns sooner or later and see the flag removed which will likely be yet another impetus fueling a KALY PPS run.

Management engaged Goldman Small Cap Research to conduct analyst coverage of the company and file an initial analyst report: KALY Research Report

Disclaimer/Safe Harbor:

This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur.

Source: www.nextbigticker.com